Trexquant Investment’s Cullinan Oncology CGEM Stock Holding History

Trexquant Investment’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.77M	Sell	152,163 -16,310	-10%	-$242K	0.02%	1046
2026 Q1	$2.39M	Sell	168,473 -213,062	-56%	-$2.74M	0.02%	928
2025 Q4	$3.95M	Buy	381,535 +193,917	+103%	+$1.75M	0.04%	701
2025 Q3	$1.11M	Buy	187,618 +68,276	+57%	+$500K	0.01%	1116
2025 Q2	$899K	Buy	119,342 +50,875	+74%	+$409K	0.01%	1139
2025 Q1	$518K	Buy	+68,467	New	+$657K	0.01%	1265
2024 Q1	–	Sell	-34,955	Closed	-$356K	–	1459
2023 Q4	$356K	Buy	+34,955	New	+$310K	0.01%	1202
2023 Q1	–	Sell	-10,249	Closed	-$108K	–	1469
2022 Q4	$108K	Sell	10,249 -13,408	-57%	-$163K	﹤0.01%	1313
2022 Q3	$303K	Sell	23,657 -8,194	-26%	-$110K	0.01%	1034
2022 Q2	$408K	Buy	+31,851	New	+$361K	0.02%	945

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Trexquant Investment's CGEM Position: Q2 2026 in Review

Trexquant Investment reduced its Cullinan Oncology (CGEM) stake by 9.7% in Q2 2026, selling an estimated $242K and leaving 152,163 shares worth $2.77M. The position accounts for 0.02% of the portfolio, ranked #1046.

Trexquant Investment first reported a position in CGEM in Q2 2022 and has held it in 10 quarters since. The position peaked at $3.95M in Q4 2025. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

Trexquant Investment held 152,163 shares of Cullinan Oncology worth $2.77M as of Q2 2026.
Trexquant Investment sold 16,310 Cullinan Oncology shares in Q2 2026, an estimated $242K.
Cullinan Oncology made up 0.02% of Trexquant Investment's portfolio in Q2 2026, its #1046 holding.
Trexquant Investment first reported a position in Cullinan Oncology in Q2 2022 and has held it in 10 quarters since.
Trexquant Investment's Cullinan Oncology position peaked at $3.95M in Q4 2025.
184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.